Acute Hemodynamic Effects of Intravenous Sildenafil Citrate in Congestive Heart Failure: Comparison of Phosphodiesterase Type-3 and -5 Inhibition

Journal of Heart and Lung Transplantation

Volumn 28, Issue 7, 2009, Pages 676-682

  Botha, Phil ^a   Parry, Gareth ^a   Dark, John H ^a   MacGowan, Guy A ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MILRINONE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE V; SILDENAFIL;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; ENZYME INHIBITION; FEMALE; HEART CATHETERIZATION; HEART INDEX; HEART LEFT VENTRICLE FILLING; HEART RATE; HEART TRANSPLANTATION; HUMAN; LOW DRUG DOSE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; LUNG WEDGE PRESSURE; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTEMIC VASCULAR RESISTANCE;

ADULT; BLOOD PRESSURE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; FEMALE; HEART FAILURE; HEART RATE; HEART TRANSPLANTATION; HUMANS; HYPERTENSION, PULMONARY; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MILRINONE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PULMONARY WEDGE PRESSURE; PURINES; SULFONES; VASCULAR RESISTANCE;

EID: 67649114159     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.04.013     Document Type: Article

References (31)

1. Delgado J.F., Conde E., Sanchez V., et al. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail 7 (2005) 1011-1016
2. Wallis R.M., Corbin J.D., Francis S.H., and Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 83 (1999) 3-12C
3. Alaeddini J., Uber P.A., Park M.H., Scott R.L., Ventura H.O., and Mehra M.R. Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. American Journal of Cardiology 94 (2004) 1475-1477
4. Senzaki H., Smith C.J., Juang G.J., et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates {beta}-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J 15 (2001) 1718-1726
5. Loughney K., Hill T.R., Florio V.A., et al. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3,′5′-cyclic nucleotide phosphodiesterase. Gene 216 (1998) 139-147
6. Nagendran J., Archer S.L., Soliman D., et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116 (2007) 238-248
7. Das A., Xi L., and Kukreja R.C. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 280 (2005) 12944-12955
8. Takimoto E., Belardi D., Tocchetti C.G., et al. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5. Circulation 115 (2007) 2159-2167
9. Borlaug B.A., Melenovsky V., Marhin T., Fitzgerald P., and Kass D.A. Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation 112 (2005) 2642-2649
10. Takimoto E., Champion H.C., Li M., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11 (2005) 214-222
11. Hassan M.A., and Ketat A.F. Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. BMC Pharmacol 5 (2005) 10
12. Fisher P.W., Salloum F., Das A., Hyder H., and Kukreja R.C. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111 (2005) 1601-1610
13. Kojda G., Kottenberg K., Nix P., Schluter K.D., Piper H.M., and Noack E. Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocytes. Circulation research 78 (1996) 91-101
14. Vila-Petroff M.G., Younes A., Egan J., Lakatta E.G., and Sollott S.J. Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. Circulation research 84 (1999) 1020-1031
15. Mohan P., Brutsaert D.L., Paulus W.J., and Sys S.U. Myocardial contractile response to nitric oxide and cGMP. Circulation 93 (1996) 1223-1229
16. Martin-Morales A., Haro J.M., Beardsworth A., Bertsch J., Kontodimas S., and Group E. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS). [erratum appears in Eur Urol 2007 Jul;52:304-6]. Eur Urol 51 (2007) 541-550 discussion 550
17. Sastry B.K., Narasimhan C., Reddy N.K., and Raju B.S. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. [see comment]. J Am Coll Cardiol 43 (2004) 1149-1153
18. Wilkins M.R., Paul G.A., Strange J.W., et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. [see comment]. Am J Respir Crit Care Med 171 (2005) 1292-1297
19. Ghofrani H.A., Wiedemann R., Rose F., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. [see comment]. Lancet 360 (2002) 895-900
20. Lepore J.J., Dec G.W., Zapol W.M., Bloch K.D., and Semigran M.J. Combined administration of intravenous dipyridamole and inhaled nitric oxide to assess reversibility of pulmonary arterial hypertension in potential cardiac transplant recipients. J Heart Lung Transplant 24 (2005) 1950
21. Jackson G., Benjamin N., Jackson N., and Allen M.J. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 83 (1999) 13-20C
22. Angel Gomez-Sanchez M., Saenz De La Calzada C., Escribano Subias P., et al. Pilot assessment of the response of several pulmonary hemodynamic variables to sublingual sildenafil in candidates for heart transplantation. Eur J Heart Fail 6 (2004) 615-617
23. Guazzi M., Tumminello G., Di Marco F., Fiorentini C., and Guazzi M.D. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 44 (2004) 2339-2348
24. Al-Hesayen A., Floras J.S., and Parker J.D. The effects of intravenous sildenafil on hemodynamics and cardiac sympathetic activity in chronic human heart failure. Eur J Heart Fail 8 (2006) 864-868
25. Forfia P.R., Lee M., Tunin R.S., Mahmud M., Champion H.C., and Kass D.A. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol 49 (2007) 1079-1088
26. Packer M., Carver J.R., Rodeheffer R.J., et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325 (1991) 1468-1475
27. Cuffe M.S., Califf R.M., Adams Jr. K.F., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287 (2002) 1541-1547
28. MacGowan G.A. Clinical overview of the novel inotropic agent toborinone. Expert Opin Investig Drugs 9 (2000) 1109-1117
29. MacGowan G.A., and Koretsky A.P. Inotropic and energetic effects of altering the force-calcium relationship: mechanisms, experimental results, and potential molecular targets. J Cardiac Fail 6 (2000) 144-156
30. Ding B., Abe J., Wei H., et al. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation 111 (2005) 2469-2476
31. Sackner-Bernstein J.D., Kowalski M., Fox M., and Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293 (2005) 1900-1905